Screener
Ligand Pharmaceuticals LGND Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| June 30, 2026 | Amortized cost | Gross unrealized gains | Gross unrealized losses | Estimated fair value |
|---|---|---|---|---|
| Corporate notes/bonds | 52,307 | — | (130) | 52,177 |
| Corporate equity securities | 20,850 | 63,477 | (3,314) | 81,013 |
| Commercial paper | 7,430 | — | (6) | 7,424 |
| Total short-term investments | $291,586 | $63,477 | $(4,007) | $351,056 |
| December 31, 2025 | ||||
| U.S. Government Agencies | $175,780 | $89 | $(38) | $175,831 |
| Corporate notes/bonds | 124,249 | 98 | (52) | 124,295 |
| U.S. Treasuries | 113,055 | 137 | (4) | 113,188 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's cumulative cost basis?
- Ligand Pharmaceuticals (LGND) reported cumulative cost basis of $291.59M in Q2 2026.
- How has Ligand Pharmaceuticals's cumulative cost basis changed year-over-year?
- Ligand Pharmaceuticals's cumulative cost basis increased by 93.5% year-over-year, from $150.73M to $291.59M.
- What is the long-term trend for Ligand Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's cumulative cost basis has grown at a 9.2% compound annual growth rate (CAGR), from $324.57M to $503.29M.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about Ligand Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude